Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleAccepted Articles

Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network

Robert D. Inman, Denis Choquette, Majed Khraishi, Dafna Gladman, Shamiza Hussein, Drew Neish and Patrick Leclerc
The Journal of Rheumatology January 2023, jrheum.220824; DOI: https://doi.org/10.3899/jrheum.220824
Robert D. Inman
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Choquette
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Majed Khraishi
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dafna Gladman
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shamiza Hussein
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Drew Neish
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Leclerc
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition consisting of two clinical subsets: non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), the latter having an estimated prevalence of 0.2 to 1% in Canada. Secukinumab received Health Canada approval in 2016 for the treatment of adults with axSpA who have responded inadequately to conventional treatment, and has demonstrated efficacy and safety through extensive clinical trials. However, there is limited evidence on its real-world use in Canada. The objective of this study was to use the Canadian Spondyloarthritis (CanSpA) Research Network to describe real-world retention and effectiveness of secukinumab in the Canadian axSpA population.

Methods This was an observational cohort study of Canadian axSpA patients ages 18-65 years within the CanSpA network that had received treatment with secukinumab. Patients were indexed on first date of secukinumab initiation. Retention and clinical effectiveness were assessed at 12-months post-index. Clinical effectiveness was measured as proportion in remission and change in disease activity using multiple clinical indices.

Results 146 patients were included. Overall retention was estimated at 62.9%. Low disease activity (BASDAI <4) was achieved in 29.2% of patients, and 2.0% had achieved ASDAS-based remission. BASMI scores improved by >60% from baseline to 12-months.

Conclusion The results of this real-world study of Canadian axSpA patients, one of the first of its kind, support the effectiveness of secukinumab for treatment of axSpA. The CanSpA network presents an opportunity to continue building and improving the real-world evidence base for treatment of Canadian patients with SpA.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 50, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accepted manuscript
Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network
Robert D. Inman, Denis Choquette, Majed Khraishi, Dafna Gladman, Shamiza Hussein, Drew Neish, Patrick Leclerc
The Journal of Rheumatology Jan 2023, jrheum.220824; DOI: 10.3899/jrheum.220824

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accepted manuscript
Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network
Robert D. Inman, Denis Choquette, Majed Khraishi, Dafna Gladman, Shamiza Hussein, Drew Neish, Patrick Leclerc
The Journal of Rheumatology Jan 2023, jrheum.220824; DOI: 10.3899/jrheum.220824
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Understanding Differences in Patient Descriptions of RA Flares Using OMERACT Core Domains
  • Do Patterns of Early Disease Severity Predict Grade 12 Academic Achievement in Youths with Childhood-onset Chronic Rheumatic Diseases?
  • Epidemiology and survival of systemic sclerosis–sarcoidosis overlap syndrome
Show more Accepted Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire